Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. - Wikidata - awgldk - TriplyDB

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.

http://www.wikidata.org/entity/Q34116065

about

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity Modulation of GITR for cancer immunotherapy Targeting regulatory T cells in cancer Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Malignant B cells induce the conversion of CD4+CD25- T cells to regulatory T cells in B-cell non-Hodgkin lymphoma GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.Regulatory T cells in HIV immunotherapy Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells.Pharmacological modulation of GITRL/GITR system: therapeutic perspectives.IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results.Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Combination immune therapies to enhance anti-tumor responses by NK cells.Role of tumor microenvironment in tumorigenesis.Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation.Tumor evasion from T cell surveillance.T-regulatory cells: key players in tumor immune escape and angiogenesis.Advances in the development of cancer immunotherapies.Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies.Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals.Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice.Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity.Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study.Distinct in vivo CD8 and CD4 T cell responses against normal and malignant tissues.Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.The expression levels of transcription factors T-bet, GATA-3, RORγt and FOXP3 in peripheral blood lymphocyte (PBL) of patients with liver cancer and their significance.Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis.Modulation of Treg cells/T effector function by GITR signaling is context-dependent.Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.Increased frequency of CD4+ CD25+ FOXP3+ cells correlates with the progression of 4-nitroquinoline1-oxide-induced rat tongue carcinogenesis.Prophylactic DNA vaccine targeting Foxp3(+) regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model.Modulation of tumor immunity: a patent evaluation of WO2015026684A1.

P2860

Q24629841-6C151C1B-F189-4DDD-AAF9-C59E4993D3AF Q26800155-44111B0B-BB3E-4346-9964-99A5006824FC Q26853557-5C8E5AB4-2BAE-4525-BDFE-F2FEB0F30345 Q27022348-592CF70C-403F-4BD5-B2EA-33D13391BFAB Q33707098-3A9E5957-1895-432B-B748-AE96D1C6B37E Q34103249-BC64E475-4A64-4AAB-AF4B-6B6448920302 Q34397451-86B9B3A2-E183-48D7-8A44-71690CEDAFCA Q34634220-6D2F6EED-840D-4ABA-8BF1-6012CE34B15F Q34725547-61A972B2-D219-403B-B964-1F8BD10968FA Q35551328-B3BF20C6-3067-4F2D-BC1A-CB6DE06920BD Q36147260-BB48EBC8-A2AB-4955-8990-CB33AA4D7D09 Q36405905-BBA0D9AB-D25D-4582-8910-F6B5B52C6696 Q36624367-FF225FD3-8B10-4391-A21C-C640C4D11165 Q36907372-1AC7172F-031C-43E9-9C52-83940824EBE6 Q37408550-5E34C2EA-CA08-457B-884C-1360525EB84F Q37738074-2E78E5B7-1A70-4824-8A52-B4928034B496 Q37788679-90A9369E-7BC6-44A7-841E-962541F4C8FD Q37799255-D9E226B4-89F1-4C4C-B9C1-F57704583E6A Q37970674-1292AE74-5E9C-4710-B2DA-34FE72198BA9 Q38006901-82FD3085-24A3-4CEB-8191-14454F7378F6 Q38049010-205F3626-F6B1-4892-A17D-7D5D011F76A8 Q38131758-F56EB6F8-AFB5-4CE4-B7A8-C019CBE3A5B7 Q38154151-D3FEEEC2-BFDC-473C-BB3F-37474F945E24 Q38161367-21E82B43-333C-4F69-911B-CF6D5C55B2A7 Q38769921-82C3C56B-6A73-4233-8E99-967035258A24 Q38796338-7C25EDE2-80A4-4D43-96C6-06B89E03BD3E Q38811689-FBB89409-D83E-4379-BCC9-2ED476862233 Q38821875-EB7EA353-AECD-4A52-A039-A6401FF9C6B7 Q38831262-076BF7C5-88A3-4944-8274-1D6A5E922691 Q39026688-97CB6920-E7F8-43A8-8487-D58F86451A68 Q39100186-70433DCA-56DF-47D7-B744-5DF7DCFA2DF0 Q39313057-6031BD32-34C8-47BF-B431-A20D9E71F120 Q41412439-F739685B-BD51-409A-B91D-10F9046494C1 Q41892056-F0207C1F-B5FE-4CBD-9175-14B5F1BDB09E Q41927855-3726DA11-5A5F-41B1-B84A-6A7CAFD50A8B Q42260874-12351371-CCD7-4FC6-9CDE-C3A5567B319A Q44922206-774F29C3-68C6-4B06-8FD1-723AF634512E Q46232858-3B9956C3-67FE-4DC1-AC70-1F802C8AC6BA Q46264331-9DBEB1AA-3A71-4574-807B-AD57AFFE4E8C Q46640448-E9984860-91F9-47AA-A3C8-9FA5353809FA

P2860

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.

http://www.wikidata.org/entity/Q34116065

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@ast

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@en

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@nl

type

label

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@ast

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@en

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@nl

prefLabel

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@ast

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@en

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@nl

P1433

Q34116065-2BFA656B-B2C7-4330-B136-17779637F805

P1476

Q34116065-D3A0357E-32CE-4C1F-8C83-188FB3EE8294

P2093

Q34116065-1BFEA222-AC89-4D3E-AF77-3882923F3717

Q34116065-2BCEFDF3-B0D1-493A-8359-9E6B3D67B681

Q34116065-834A2E85-36F2-4AD3-998D-CACCB9FFCF69

Q34116065-CC628DA0-7A81-452A-AEBC-AC0899C18F78

Q34116065-EBDF2E32-EFB5-49B7-BD7C-807D5EFA0AA1

Q34116065-FC71BEBB-A66D-4662-BE85-B2ED21948878

P2860

Q34116065-278C6A56-8859-4972-A3FB-AA50344E438E

Q34116065-4CFBF0EF-7740-45BE-B1C5-DB5BC36515A7

Q34116065-516B4BC9-9094-46D2-933F-BA10CB3C47B8

Q34116065-8648AD5A-DD89-48DB-B9B1-F26CE02A992B

Q34116065-86AFA588-27BC-4B4E-9749-3126F453460A

Q34116065-B2E112F6-3B80-40CB-A171-353F7C05F4C0

Q34116065-C47583F5-D641-4C64-8188-606176ED325C

Q34116065-E7C1D846-C866-486A-BF74-82F1DC03E7DF

P2888

Q34116065-8CEA07F4-F258-4752-8026-61B9690E0006

P304

Q34116065-9A22F6E4-2282-45BA-9FFE-FD1905287527

P31

Q34116065-B65D5268-EBF7-432B-A0E0-D29F3F297BEE

P356

Q34116065-BE2B007D-B35E-47C7-B6E9-245D4C441877

P433

Q34116065-AC338750-BFE1-4A81-BA08-4AB76E9E8A2C

P478

Q34116065-3BF49ED4-D7A0-41DA-A65F-B051FA7CCF9E

P577

Q34116065-A0FB0196-8ABE-40AB-9553-9CD1EC74D3B4

P5875

Q34116065-01267B2E-3F9A-4D02-AABC-1E7740E172EA

P6179

Q34116065-F2374A2F-04C4-4305-B4C8-2F2CC4E6D6DA

P698

Q34116065-BCDF90BC-39B0-4FFC-B7B2-D060DC821AAB

P921

Q34116065-C2980814-8749-41E4-8431-F1BECD99EE32

P356

S00262-010-0866-5

P1433

Cancer Immunology, Immunotherapy

P1476

Depletion of regulatory T cell ...... nism for cancer immunotherapy.

@en

P2093

Caroline Addey

http://www.w3.org/2001/XMLSchema#string

David Coe

http://www.w3.org/2001/XMLSchema#string

Jian-Guo Chai

http://www.w3.org/2001/XMLSchema#string

Julian Dyson

http://www.w3.org/2001/XMLSchema#string

Matthew White

http://www.w3.org/2001/XMLSchema#string

Shaima Begom

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells.

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells.

Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression.

Interleukin-5 modulates eosinophil accumulation in allergic guinea pig lung.

Th2 lymphoproliferative disorder of LatY136F mutant mice unfolds independently of TCR-MHC engagement and is insensitive to the action of Foxp3+ regulatory T cells.

Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis.

Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells.

P2888

s00262-010-0866-5

P304

1367-1377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0866-5

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44609241

http://www.w3.org/2001/XMLSchema#string

P6179

1037129194

http://www.w3.org/2001/XMLSchema#string

P698

20480365

http://www.w3.org/2001/XMLSchema#string

P921